probiotica - melkzuurbacterien verbeteren constipatie bij patiënten met de ziekte van Parkinson.

3 maart 2021: Bron: Journal of the anus, rectum and colon.

Constipatie komt veel voor bij patiënten met de ziekte van Parkinson en die constipatie kan ernstige problemen veroorzaken. Tot aan overlijden aan toe. Uit een dubbelblinde en gerandomiseerde placebo gecontroleerde studie blijkt dat probiotica - melkzuurbacteriën de problemen met constipatie kunnen verlichten en verbeteren.

Het gemiddelde aantal wekelijkse spontane stoelgangen nam toe in de behandelingsgroep met 1,0 - 1,2 keer vanaf de 2 weken dat met de probiotica werd begonnen tot de laatste 2 weken van de studie (baseline, 2,6), en nam af met 0,3 in de placebogroep (baseline, 2.8). Secundaire uitkomsten, waaronder kwaliteit van leven gerelateerd aan constipatie, waren ook gunstig voor de actieve behandeling. Er werden geen ernstige bijwerkingen gezien.

Op de website waar deze studie is gepubliceerd kunt u een PDF downloaden van de studie:

Lewy body constipation

Sakakibara R, Doi H, Fukudo S. Lewy body constipation. J Anus Rectum Colon. 2019;3(1):10-17.

Ryuji Sakakibara, Hirokazu Doi, Shin Fukudo

Author information

Abstract

We systematically reviewed literature regarding "Lewy body constipation", i.e., constipation due to Lewy body diseases (LBD), with minimal neurologic symptoms. Epidemiology and pathology studies showed that LBD can start with constipation alone, mostly due to neuronal loss and appearance of Lewy bodies in the myenteric plexus. Because LBD significantly increases with age, "Lewy body constipation" may also increase with age. Neuroimaging methods such as metaiodobenzylguanidine (MIBG) scintigraphy and dopamine transporter (DAT) scan provide a way to detect "Lewy body constipation." Key for "Lewy body constipation" includes minimal non-motor features such as REM sleep behavior disorder (night talking). Add-on therapy may be required to ameliorate constipation in patients. Diagnosis is not always easy; therefore, collaboration of gastroenterologists and neurologists is highly recommended to maximize patients' quality of life. In conclusion, "Lewy body constipation" might become a distinct category among geriatric constipation, regarding patients' follow-up and their management.

Fullsize Image

References (46)

1. Cotterill N, Madersbacher H, Wyndaele JJ, Apostolidis A, Drake MJ, Gajewski J, Heesakkers J, Panicker J, Radziszewski P, Sakakibara R, Sievert KD, Hamid R, Kessler TM, Emmanuel A. Neurogenic bowel dysfunction: clinical management recommendations of the neurologic incontinence Committee of the Fifth International Consultation on Incontinence 2013. Neurourol Urodyn. 2018; 37: 46-53.

2. Ghoshal UC. Chronic constipation in Rome IV era: The Indian perspective. Indian J Gastroenterol. 2017; 36: 163-73.

3. Drossman DA, Chang L, Chey WC, Kellow J, Tack J, Whitehead WE, etd. Rome IV Functional Gastrointestinal Disorders: Disorders of Gut-Brain Interaction, Volume 1 and 2, Rome Foundation, Inc., New York, 2017.

4. Downes TJ, Cheruvu MS, Karunaratne TB, De Giorgio R, Farmer AD. Pathophysiology, diagnosis, and management of chronic intestinal pseudo-obstruction. J Clin Gastroenterol. 2018; 52: 477-89.

5. Tateno F, Sakakibara R, Kishi M, Ogawa E, Takada N, Hosoe N, et al. Constipation and metaiodobenzylguanidine myocardial scintigraphy abnormality. J Am Geriatr Soc. 2012; 60: 185-7.

6. Sakakibara R, Tateno F, Kishi M, Tsuyusaki Y, Terada H, Inaoka T. MIBG myocardial scintigraphy in pre-motor Parkinson's disease: a review. Parkinsonism Relat Disord. 2014; 20: 267-73.

7. Tateno H, Sakakibara R, Tateno F, Tuyusaki Y, Aiba Y, Kishi M, Tateno A, Ogata T, Doi H, Inaoka T, Terada H, Suzuki Y. Metaiodobenzylguanidine myocardial scintigraphy identifies premotor parkinson's disease during a negative dopamine transporter scan. J Am Geriatr Soc. 2015; 63: 2428-30.

8. Yamashina S, Yamazaki J. Neuronal imaging using SPECT. Eur J Nucl Med Mol Imaging 2007; 34: 939-50.

9. Orimo S, Uchihara T, Nakamura A, Mori F, Kakita A, Wakabayashi K, et al. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease. Brain 2008; 131: 642-50.

10. Nuvoli S, Palumbo B, Malaspina S, Madeddu G, Spanu A. 123I-ioflupane SPET and 123I-MIBG in the diagnosis of Parkinson's disease and parkinsonian disorders and in the differential diagnosis between Alzheimer's and Lewy's bodies dementias. Hell J Nucl Med. 2018; 21: 60-68.

11. Treglia G, Cason E, Stefanelli A, Cocciolillo F, Di Giuda D, Fagioli G, et al. MIBG scintigraphy in differential diagnosis of Parkinsonism: a meta-analysis. Clin Auton Res. 2012; 22: 43-55.

12. Satoh A, Serita T, Seto M, Tomita I, Satoh H, Iwanaga K, et al. Loss of 123I-MIBG uptake by the heart in Parkinson's disease: assessment of cardiac sympathetic denervation and diagnostic value. J Nucl Med 1999; 40: 371-5.

13. Brandl SJ, Braune S. Sensitivity and specificity of cardiac metaiodobenzylguanidine scintigraphy in the early diagnosis of Parkinson's disease. Clin Auton Res. 2018 Jun 5. doi: 10.1007/s10286-018-0534-y. [Epub ahead of print]

14. Kobayashi S, Makino K, Hatakeyama S, Ishii T, Tateno M, Iwamoto T, Tsujino H, Kawasaki K, Mikuni K, Ukai W, Murayama T, Hashimoto E, Utsumi K, Kawanishi C. The usefulness of combined brain perfusion single-photon emission computed tomography, dopamine-transporter single-photon emission computed tomography, and 123 I-metaiodobenzylguanidine myocardial scintigraphy for the diagnosis of dementia with Lewy bodies. Psychogeriatrics 2017; 17: 247-55.

15. Iranzo A, Valldeoriola F, Lomeña F, Molinuevo JL, Serradell M, Salamero M, Cot A, Ros D, Pavía J, Santamaria J, Tolosa E. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol. 2011; 10: 797-805.

16. Abbott RD, Petrovitch H, White LR, Masaki KH, Tanner CM, Curb JD, et al. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 2001; 57: 456-62.

17. Hawkes CH, Del Tredici K, Braak H. A timeline for Parkinson's disease. Parkinsonism and Related Disorders 2010; 16: 79-84.

18. Gelpi E, Navarro-Otano J, Tolosa E, Gaig C, Compta Y, Rey MJ, Martí MJ, Hernández I, Valldeoriola F, Reñé R, Ribalta T. Multiple organ involvement by alpha-synuclein pathology in Lewy body disorders. Mov Disord. 2014; 29: 1010-8.

19. Yan D, Zhang Y, Liu L, Shi N, Yan H. Pesticide exposure and risk of Parkinson's disease: Dose-response meta-analysis of observational studies. Regul Toxicol Pharmacol. 2018; 96: 57-63.

20. McCann H, Cartwright H, Halliday GM. Neuropathology of α-synuclein propagation and braak hypothesis. Mov Disord. 2016; 31: 152-60.

21. FeliceVD, Quigley EM, Sullivan AM, O'Keeffe GW, O'Mahony SM. Microbiota-gut-brain signalling in Parkinson's disease: Implications for non-motor symptoms. Parkinsonism Relat Disord. 2016; 27: 1-8.

22. Pan-Montojo F, Anichtchik O, Dening Y, Knels L, Pursche S, Jung R, Jackson S, Gille G, Spillantini MG, Reichmann H, Funk RH. Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice. PLoS ONE. 2010; 5: e8762.

23. Svensson E, Horváth-Puhó E, Thomsen RW, Djurhuus JC, Pedersen L, Borghammer P, Sørensen HT. Vagotomy and subsequent risk of Parkinson's disease. Ann Neurol. 2015; 78: 522-9.

24. Hansen MB. Neurohumoral control of gastrointestinal motility. Physiol. Res. 2003; 52: 1-30.

25. Sakakibara R, Kishi M, Ogawa E, Tateno F, Uchiyama T, Yamamoto T, Yamanishi T. Bladder, bowel, and sexual dysfunction in Parkinson's disease. Parkinsons Dis. 2011; 2011: 924605.

26. Weng Y, Qi R, Liu C, Ke J, Xu Q, Wang F, Zhang LJ, Lu GM. Disrupted functional connectivity density in irritable bowel syndrome patients. Brain Imaging Behav. 2017; 11: 1812-22.

27. Schaller BJ, Graf R, Jacobs AH. Pathophysiological changes of the gastrointestinal tract in ischemic stroke. Am J Gastroenterol. 2006; 101: 1655-65.

28. Sakakibara R. Cyclic vomiting syndrome: the nervous system has the guts. Clin Auton Res. 2018; 28: 167-9.

29. Mukherjee A, Biswas A, Das SK. Gut dysfunction in Parkinson's disease. World J Gastroenterol. 2016; 22: 5742-52.

30. Bestetti A, Capozza A, Lacerenza M, Manfredi L, Mancini F. Delayed gastric emptying in advanced Parkinson disease: correlation with therapeutic doses. Clin Nucl Med. 2017; 42: 83-7.

31. Tateno F, Sakakibara R, Kishi M, Ogawa E, Yoshimatsu Y, Takada N, Suzuki Y, Mouri T, Uchiyama T, Yamamoto T. Incidence of emergency intestinal pseudo-obstruction in Parkinson's disease. J Am Geriatr Soc. 2011; 59: 2373-5.

32. Ogawa E, Sakakibara R, Kishi M, Tateno F. Constipation triggered the malignant syndrome in Parkinson's disease. Neurol Sci. 2012; 33: 347-50.

33. Tateno F, Sakakibara R, Aiba Y, Tsuyusaki Y, Kishi M, Tateno H, Ogata T. Stercoral ulcer and colonic perforation in an individual with Parkinson's disease with constipation. J Am Geriatr Soc. 2016; 64: e118-20.

34. Tateno F, Sakakibara R, Yokoi Y, Kishi M, Ogawa E, Uchiyama T, Yamamoto T, Yamanishi T, Takahashi O. Levodopa ameliorated anorectal constipation in de novo Parkinson's disease: The QL-GAT study. Parkinsonism Relat Disord. 2011; 17: 662-6.

35. Tateno H, Sakakibara R, Shiina S, Doi H, Tateno F, Sato M, Masaka T, Kishi M, Tsuyusaki Y, Aiba Y, Ogata T, Suzuki Y. Transdermal dopamine agonist ameliorates gastric emptying in Parkinson's disease. J Am Geriatr Soc. 2015; 63: 2416-8.

36. Rao SS, Beaty J, Chamberlain M, Lambert PG, Gisolfi C. Effects of acute graded exercise on human colonic motility. Am J Physiol. 1999; 276 (5 Pt 1): G1221-6.

37. Takano S, Sands DR. Influence of body posture on defecation: a prospective study of "The Thinker" position. Tech Coloproctol. 2016; 20: 117-21.

38. Zangaglia R, Martignoni E, Glorioso M, Ossola M, Riboldazzi G, Calandrella D, Brunetti G, Pacchetti C. Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study. Mov Disord. 2007; 22: 1239-44.

39. Sakakibara R, Yamaguchi T, Uchiyama T, Yamamoto T, Ito T, Liu Z, Odaka T, Yamaguchi C, Hattori T. Calcium polycarbophil improves constipation in primary autonomic failure and multiple system atrophy subjects. Mov Disord. 2007; 22: 1672-3.

40. Ondo WG, Kenney C, Sullivan K, Davidson A, Hunter C, Jahan I, McCombs A, Miller A, Zesiewicz TA. Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease. Neurology. 2012; 78: 1650-4.

41. Liu Z, Sakakibara R, Odaka T, Uchiyama T, Uchiyama T, Yamamoto T, Ito T, Asahina M, Yamaguchi K, Yamaguchi T, Hattori T. Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients. Mov Disord. 2005; 20: 680-6.

42. Sullivan KL, Staffetti JF, Hauser RA, Dunne PB, Zesiewicz TA. Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease. Mov. Disord. 2006; 21: 115-6.

43. Sakakibara R, Doi H, Sato M, Hirai S, Masaka T, Kishi M, Tsuyusaki Y, Tateno A, Tateno F, Aiba Y, Ogata T, Suzuki Y. Nizatidine ameliorates slow transit constipation in Parkinson's disease. J Am Geriatr Soc. 2015; 63: 399-401.

44. Sakakibara R, Odaka T, Lui Z, Uchiyama T, Yamaguchi K, Yamaguchi T, Asahina M, Yamamoto T, Ito T, Hattori T. Dietary herb extract dai-kenchu-to ameliorates constipation in parkinsonian patients (Parkinson's disease and multiple system atrophy). Mov Disord. 2005; 20: 261-2.

45. Doi H, Sakakibara R, Sato M, Hirai S, Masaka T, Kishi M, Tsuyusaki Y, Tateno A, Tateno F, Takahashi O, Ogata T. Dietary herb extract rikkunshi-to ameliorates gastroparesis in Parkinson's disease: a pilot study. Eur Neurol. 2014; 71: 193-5.

46. Cadeddu F, Bentivoglio AR, Brandara F, Marniga G, Brisinda G, Maria G. Outlet type constipation in Parkinson's disease: results of botulinum toxin treatment. Aliment Pharmacol. Ther. 2005; 22: 997-1003.

Ziekte van Parkinson, constipatie, probiotica, darmflora, melkzuurbacterien